Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18,685 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy.
Huang J, Su R, Chen Z, Jiang S, Chen M, Yuan Y, Hu H, Fu C, Huang Z, Wang Z, Zheng B, Li C, Wang Z, Bao Y, Cai M, Guo J, Wei Q, Xue W. Huang J, et al. Among authors: hu h. Oncoimmunology. 2022 Sep 17;11(1):2124691. doi: 10.1080/2162402X.2022.2124691. eCollection 2022. Oncoimmunology. 2022. PMID: 36148322 Free PMC article.
Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle-invasive bladder cancer: A multi-center, single-arm, phase 2 study.
Han S, Ji Z, Jiang J, Fan X, Ma Q, Hu L, Zhang W, Ping H, Wang J, Xu W, Shi B, Wang W, Wang H, Wang H, Chen S, Hu H, Guo J, Zhang S, Jiang S, Zhou Q, Xing N. Han S, et al. Among authors: hu h, hu l. Cancer Med. 2023 Jun;12(11):12106-12117. doi: 10.1002/cam4.5900. Epub 2023 Apr 6. Cancer Med. 2023. PMID: 37021811 Free PMC article. Clinical Trial.
18,685 results
You have reached the last available page of results. Please see the User Guide for more information.